Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
Dogwood Therapeutics, Inc. (DWTX)
Company Research
Source: GlobeNewswire
Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected to commence in the middle of 2026 at the University of Virginia ALPHARETTA, Ga., April 15, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (NASDAQ: DWTX) (“DWTX”, “Dogwood” or “the Company”), a company that focuses on developing new non-opioid medicines to treat pain and neuropathy, today announced FDA acceptance of an Investigational New Drug (“IND”) application for its development candidate SP16, administered intravenously (“IV”), for the treatment of chemotherapy-induced pain and peripheral neuropathy (“CIPPN”). SP16 is administered via IV infusion with two hypothesized actions: anti-inflammatory actions via reduction of IL-6, IL-8, IL-1ß and TNF-alpha, and tissue repair via increases in pAKT and pERK that regulate and promote fundamental processes like growth, proliferation,
Show less
Read more
Impact Snapshot
Event Time:
DWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DWTX alerts
High impacting Dogwood Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
DWTX
News
- Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
- Dogwood Therapeutics (NASDAQ:DWTX) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- DWTX: Financing Secures Funding Through Phase 2b Data Readout [Yahoo! Finance]Yahoo! Finance
- Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026 [Yahoo! Finance]Yahoo! Finance
DWTX
Earnings
- 11/6/25 - Miss
DWTX
Sec Filings
- 3/26/26 - Form 8-K
- 3/18/26 - Form 10-K
- 3/18/26 - Form 8-K
- DWTX's page on the SEC website